[at Motley Fool] – Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect its top line for investors?
Read more on this.
Bristol-Myers Squibb … [visit site to read more]
Bristol-Myers Squibb Company (NYSE:BMY) ~ How Will the Top Line Change for Repligen in 2014?
January 10, 2014 at 11:42 AM EST
[at Motley Fool] – Repligen will lose an important royalty revenue stream from Bristol-Myers Squibb this year. How will that affect its top line for investors? Read more on this. Bristol-Myers Squibb . . . → Read More: Bristol-Myers Squibb Company (NYSE:BMY) ~ How Will the Top Line Change for Repligen in 2014?
